People who have Crohn's disease or multiple sclerosis may benefit from receiving natalizumab ever four weeks. Specifically, this medicine can help reduce relapses in people with multiple sclerosis and relieve symptoms caused by Crohn's disease. Your healthcare provider will administer this drug intravenously (by IV). Side effects may include joint pain, depression, and headaches.

What Is Natalizumab?

Natalizumab (Tysabri®) is a prescription medication that belongs to a group of medicines called immunomodulators. It is approved to:
  • Slow down the worsening of disability and reduce the number of relapses (times when symptoms flare up) in people with multiple sclerosis (MS)
  • Treat and prevent symptoms in people with Crohn's disease.
Whether it is used for MS or Crohn's disease, natalizumab is reserved for people who have not responded to or cannot take other medications to treat their condition.
(Click What Is Natalizumab Used For? for more information on this topic, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, natalizumab can cause side effects. However, not everyone who receives the drug will experience problems. Most people tolerate it quite well.
If reactions do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
Common side effects of natalizumab include but are not limited to:
(Click Natalizumab Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
Know the Signs - Concussion Safety

Natalizumab Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.